Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown,
NY 10591-6707
United States - Map
Phone: 914-347-7000
Fax: 914-347-2847
Website: http://www.regeneron.com
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. The companys commercial products include EYLEA (aflibercept) Injection for the treatment of neovascular age-related macular degeneration; and ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consists of EYLEA for the treatment of serious eye diseases; ZALTRAP (Aflibercept), which is developed in oncology; and ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment. The companys earlier stage clinical programs include various human monoclonal antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction; REGN88 for rheumatoid arthritis; REGN668 for atopic dermatitis and eosinophilic asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN728, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize ZALTRAP and EYLEA. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Key Statistics
| |
| Regeneron Pharmaceuticals, Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (Medium Concern), Shareholder Rights (High Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Leonard S. Schleifer M.D., Ph.D.,
59
Co-Founder, Chief Exec. Officer, Pres, Exec. Director and Ex Officio Member of Technology Committee | 3.11M | 6.00M | Dr. Alfred G. Gilman M.D., Ph.D.,
70
Co-Founder, Director, Chairman of Corp. Governance & Compliance Committee and Member of Technology Committee | 50.00K | N/A | Dr. Eric M. Shooter Ph.D.,
88
Co-Founder, Director and Member of Technology Committee | 45.00K | N/A | Mr. Murray A. Goldberg ,
67
Chief Financial Officer, Sr. VP of Fin. & Admin., Treasurer and Assistant Sec. | 842.00K | 6.59M | Mr. George D. Yancopoulos M.D., Ph.D.,
52
Chief Scientific Officer, Exec. VP, Director, Ex Officio Member of Technology Committee and Pres of Regeneron Research Laboratories | 2.58M | 6.04M |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq 
2.46(1.90%) May 25, 4:00PM EDT|After Hours:
132.17